EXICURE, INC. — fact timeline

Elias Papadimas resigned as Chief Financial Officer and Corporate Secretary at EXICURE, INC..

“Elias Papadimas resigned as Chief Financial Officer and Corporate Secretary of the Company.”

Matthias Schroff resigned as Class I Director at EXICURE, INC..

“Mr. Schroff and Seung Shoo Shin resigned from the Board as Class I and Class II Directors, respectively.”

Matthias Schroff resigned as Chief Executive Officer and President at EXICURE, INC..

“Matthias Schroff resigned as the Chief Executive Officer and President of the Company”

Jung Sang (Michael) Kim was appointed as Class II Director at EXICURE, INC..

“The Board appointed Mr. Kim to fill the Class II Director vacancy”

Jung Sang (Michael) Kim was appointed as Chief Executive Officer, Chief Financial Officer and President at EXICURE, INC..

“Jung Sang (Michael) Kim has been appointed to Chief Executive Officer, Chief Financial Officer and President by the Board of Directors (the “ Board ”) effective as of April 26, 2023.”

EXICURE, INC. reported the year ended December 31, 2022 results: revenue $28.8 million.

“status of the Company as it explores strategic alternatives and this estimate may prove inaccurate and the Company may expend its limited resources sooner. Revenue : Revenue was $28.8 million for the year ended December 31, 2022, reflecting an increase of $29.3 million from revenue of $(0.5) million for the year ended December 31, 2021. The increase in collaboration”

EXICURE, INC. underwent a change of control involving CBI USA, Inc. (closed 2023-02-24).

“As a result of the previously disclosed closing of the private placement (the “Private Placement”) to CBI USA, Inc. (“CBI”) on February 24, 2023 pursuant to the Securities Purchase Agreement dated September 26, 2022 (the “SPA”), CBI is the beneficial owner of 50.4% of the Company’s outstanding shares.”

Seung Soo Shin was appointed as Chairman of the Board at EXICURE, INC..

“The Board appointed Cheolho Jo and Seung Soo Shin to the Board, effective February 27, 2023.”

Cheolho Jo was appointed as Director at EXICURE, INC..

“The Board appointed Cheolho Jo and Seung Soo Shin to the Board, effective February 27, 2023.”

EXICURE, INC. received a nasdaq deficiency notice notice regarding board independence (rules 5605, 5605(d)(4)).

“February 21, 2023, Exicure, Inc. (the “Company”) received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is no longer in compliance with Nasdaq’s compensation committee requirements as set forth in Nasdaq Listing Rule 5605 as a result of the previously disclosed resignation of Jeffrey L. Cleland, Ph.D., effective February 10, 2023 . Nasdaq Rule 5605 requires the compensation committee of the board of directors to be comprised of at least two independent directors (the “Listing Requirement for Compensation Committee”). Pursuant to Nasdaq Listing Rules 5605(d)(4), the Compan”

Elizabeth Garofalo resigned as Director and Chair of the Board at EXICURE, INC..

“Effective February 24, 2023, following closing of the Private Placement, Elizabeth Garofalo, M.D. resigned from the Board of Directors (the “Board”) of Exicure, Inc. (the “Company”) and as chair of the Board as well as from the audit committee, compensation committee and nominating and corporate governance committee of the Board.”

Changil Ahn was appointed as Class III Director at EXICURE, INC..

“the Board appointed Paul Kang, Hyukku Lee and Changil Ahn to the Board effective February 24, 2023.”

Hyukku Lee was appointed as Class II Director at EXICURE, INC..

“the Board appointed Paul Kang, Hyukku Lee and Changil Ahn to the Board effective February 24, 2023.”

Paul Kang was appointed as Class III Director at EXICURE, INC..

“the Board appointed Paul Kang, Hyukku Lee and Changil Ahn to the Board effective February 24, 2023.”

Jeffrey L. Cleland resigned as Director at EXICURE, INC..

“Effective February 10, 2023, Dr. Cleland resigned from the Board, the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee of the Board.”

EXICURE, INC. received a nasdaq deficiency notice notice regarding audit committee (rules 5605, 5605(b)(1)(A), 5605(c)(4)).

“January 19, 2023, Exicure, Inc. (the “Company”) received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is no longer in compliance with Nasdaq’s independent director and audit committee requirements as set forth in Nasdaq Listing Rule 5605, which requires the board of directors to be comprised of a majority of independent directors and the audit committee of the board of directors to be comprised of three independent directors (the “Listing Requirement”). Pursuant to Nasdaq Listing Rules 5605(b)(1)(A) and 5605(c)(4), the Company is entitled to a cure period to regain compl”

Jiyoung Hwang resigned as Director at EXICURE, INC..

“On January 16, 2023, Jiyoung Hwang tendered her resignation from the Board, effective immediately as of such date.”

Jiyoung Hwang was appointed as Lead Purchaser Board Designee at EXICURE, INC..

“Pursuant to the May 2022 Securities Purchase Agreement, the Board appointed Jiyoung Hwang to the Board as the Lead Purchaser Board Designee (as defined in the May 2022 Securities Purchase Agreement), effective December 30, 2022.”

Bali Muralidhar resigned as Director at EXICURE, INC..

“Effective December 30, 2022 (the “Resignation Date”), James Sulat and Bali Muralidhar, M.D., Ph.D. each resigned from the Board of Directors (the “Board”) of Exicure, Inc. (the “Company”).”

James Sulat resigned as Director at EXICURE, INC..

“Effective December 30, 2022 (the “Resignation Date”), James Sulat and Bali Muralidhar, M.D., Ph.D. each resigned from the Board of Directors (the “Board”) of Exicure, Inc. (the “Company”).”

EXICURE, INC. shareholders approved Approval of one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the foregoing proposal at the 2022-12-15 meeting.

“Proposal 2 – Approval of one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the foregoing proposal. The Company’s stockholders approved Proposal 2. The votes cast were as follows: For Against Abstain 2,372,007 134,749 18,455”

EXICURE, INC. shareholders approved Approval of the issuance of shares of Common Stock in the Private Placement, which would result in a "change of control" of the Company under the applicable rules of Nasdaq at the 2022-12-15 meeting.

“Proposal 1 – Approval of the issuance of shares of Common Stock in the Private Placement, which would result in a “change of control” of the Company under the applicable rules of Nasdaq. The Company’s stockholders approved Proposal 1. The votes cast were as follows: For Against Abstain 2,392,643 114,739 17,829”

Bali Muralidhar resigned as Director at EXICURE, INC..

“On December 16, 2022, Bali Muralidhar, M.D., Ph.D. tendered his resignation from the Board as well as from the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee of the Board, effective as of the earlier of: (1) the closing date of the Private Placement (as defined below under Item 5.07), or (2) December 30, 2022.”

James Sulat resigned as Director at EXICURE, INC..

“On December 15, 2022, James Sulat tendered his resignation from the Board of Directors (the “Board”) of Exicure, Inc. (the “Company”) as well as from the Audit Committee and Nominating and Corporate Governance Committee of the Board, effective as of the earlier of: (1) the closing date of the Private Placement (as defined below under Item 5.07), or (2) December 30, 2022.”

EXICURE, INC. reported quarter ended September 30, 2022 results: revenue $2.0 million, net income $5.2 million.

“proceeds from the Private Placement as the Private Placement has not closed) will enable it to fund its current operations into the second quarter of 2023. Revenue : Revenue was $2.0 million for the quarter ended September 30, 2022, reflecting an increase of $5.7 million from revenue of $(3.7) million for the quarter ended September 30, 2021. The increase in”

EXICURE, INC. entered into Side Letter to Securities Purchase Agreement with CBI USA, Inc. valued at Confirmation of director designation rights and compliance with Nasdaq Listing Rule 5640 (effective 2022-10-31).

“On October 31, 2022, the Company and CBI USA entered into a Side Letter to Securities Purchase Agreement (“Side Letter”), pursuant to which the parties further confirmed and clarified certain agreements between the parties under the Securities Purchase Agreement, including, among other things, CBI USA’s rights to designate a majority of the Board of Directors of the Company immediately after the closing of the Private Placement and CBI USA’s ability to exercise such director designation rights together with its affiliates as a group, provided that such director designation rights are in compliance with Nasdaq Listing Rule 5640.”

David A. Giljohann departed as Chief Technology Officer at EXICURE, INC..

“David A. Giljohann, Ph.D. was appointed to the position of Chief Technology Officer of the Company through January 31, 2022, at which time Dr. Giljohann separated from the Company.”

Matthias Schroff was appointed as President and Chief Executive Officer at EXICURE, INC..

“The Board appointed Matthias Schroff, Ph.D., the Company’s current Chief Scientific Officer, to the position of President and Chief Executive Officer and as a member of the Board to succeed Mr. Bock, effective February 4, 2022.”

Brian C. Bock departed as President and Chief Executive Officer at EXICURE, INC..

“Effective February 4, 2022 (the “ Transition Date ”), Brian C. Bock will cease serving as the Company’s President and Chief Executive Officer and as a member of the Board to pursue other opportunities.”

Matthias Schroff was appointed as Chief Scientific Officer at EXICURE, INC..

“The Board appointed Matthias Schroff, the Company’s Chief Operating Officer, to the position of Chief Scientific Officer of the Company effective December 10, 2021.”

David Giljohann departed as Chief Technology Officer at EXICURE, INC..

“Dr. Giljohann will serve as Chief Technology Officer of the Company through January 30, 2022, at which time he will separate from the Company.”

David Giljohann resigned as member of the Board at EXICURE, INC..

“In connection with his transition to the position of Chief Technology Officer, Dr. Giljohann resigned as a member of the Board, effective December 10, 2021.”

David Giljohann was appointed as Chief Technology Officer at EXICURE, INC..

“The Board appointed Dr. Giljohann to the position of Chief Technology Officer of the Company effective December 10, 2021.”

Brian C. Bock was appointed as member of the Board at EXICURE, INC..

“Mr. Bock was appointed as a member of the Board, effective December 10, 2021, to fill the vacancy created by Dr. Giljohann.”

Brian C. Bock was appointed as Chief Executive Officer at EXICURE, INC..

“The Board of Directors of the Company (the “Board”) appointed Brian C. Bock, the Company’s Chief Financial Officer, as the Company’s Chief Executive Officer, replacing David Giljohann, effective December 10, 2021.”